133 related articles for article (PubMed ID: 31422923)
1. Ten-year outcomes from a randomised comparison of zotarolimus-eluting and sirolimus-eluting stents: the SORT OUT III study.
Pareek M; Madsen M; Warnakula Olesen KK; Okkels Jensen L; Høj Christiansen E; Dalby Kristensen S; Flensted Lassen J; Thuesen L; Bøtker HE; Maeng M
EuroIntervention; 2019 Dec; 15(11):e1022-e1024. PubMed ID: 31422923
[No Abstract] [Full Text] [Related]
2. Differential clinical outcomes after 1 year versus 5 years in a randomised comparison of zotarolimus-eluting and sirolimus-eluting coronary stents (the SORT OUT III study): a multicentre, open-label, randomised superiority trial.
Maeng M; Tilsted HH; Jensen LO; Krusell LR; Kaltoft A; Kelbæk H; Villadsen AB; Ravkilde J; Hansen KN; Christiansen EH; Aarøe J; Jensen JS; Kristensen SD; Bøtker HE; Thuesen L; Madsen M; Thayssen P; Sørensen HT; Lassen JF
Lancet; 2014 Jun; 383(9934):2047-2056. PubMed ID: 24631162
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomised controlled superiority trial.
Rasmussen K; Maeng M; Kaltoft A; Thayssen P; Kelbaek H; Tilsted HH; Abildgaard U; Christiansen EH; Engstrøm T; Krusell LR; Ravkilde J; Hansen PR; Hansen KN; Abildstrøm SZ; Aarøe J; Jensen JS; Kristensen SD; Bøtker HE; Madsen M; Johnsen SP; Jensen LO; Sørensen HT; Thuesen L; Lassen JF;
Lancet; 2010 Mar; 375(9720):1090-9. PubMed ID: 20231034
[TBL] [Abstract][Full Text] [Related]
4. A randomized, prospective, two-center comparison of sirolimus-eluting stent and zotarolimus-eluting stent in acute ST-elevation myocardial infarction: the SEZE trial.
Chung WY; Kang J; Cho YS; Park HJ; Yang HM; Seo JB; Suh JW; Kim KI; Youn TJ; Kim SH; Chae IH; Zo JH; Kim MA; Choi DJ
Chin Med J (Engl); 2012 Oct; 125(19):3373-81. PubMed ID: 23044291
[TBL] [Abstract][Full Text] [Related]
5. Clinical outcomes after treatment of multiple lesions with zotarolimus-eluting versus sirolimus-eluting coronary stents (a SORT OUT III substudy).
Thim T; Maeng M; Lassen JF; Kaltoft A; Jensen LO; Ravkilde J; Thayssen P; Galatius S; Christiansen EH; Engstrøm T; Madsen M; Thuesen L; Tilsted HH
BMC Cardiovasc Disord; 2012 Mar; 12():18. PubMed ID: 22429474
[TBL] [Abstract][Full Text] [Related]
6. Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials.
Bangalore S; Kumar S; Fusaro M; Amoroso N; Attubato MJ; Feit F; Bhatt DL; Slater J
Circulation; 2012 Jun; 125(23):2873-91. PubMed ID: 22586281
[TBL] [Abstract][Full Text] [Related]
7. Polymer-free sirolimus- and probucol-eluting versus new generation zotarolimus-eluting stents in coronary artery disease: the Intracoronary Stenting and Angiographic Results: Test Efficacy of Sirolimus- and Probucol-Eluting versus Zotarolimus-eluting Stents (ISAR-TEST 5) trial.
Massberg S; Byrne RA; Kastrati A; Schulz S; Pache J; Hausleiter J; Ibrahim T; Fusaro M; Ott I; Schömig A; Laugwitz KL; Mehilli J;
Circulation; 2011 Aug; 124(5):624-32. PubMed ID: 21768546
[TBL] [Abstract][Full Text] [Related]
8. Zotarolimus-eluting stent versus sirolimus-eluting and paclitaxel-eluting stents for percutaneous coronary intervention: a meta-analysis of randomized trials.
Sethi A; Bahekar A; Bhuriya R; Bajaj A; Singh PP; Arora R; Khosla S
Arch Cardiovasc Dis; 2012 Nov; 105(11):544-56. PubMed ID: 23177483
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of zotarolimus-eluting stents compared with sirolimus-eluting stents in patients undergoing percutaneous coronary interventions--a meta-analysis of randomized controlled trials.
Fan J; Du H; Yin Y; Ling Z; Wu J; Xiao P; Zrenner B
Int J Cardiol; 2013 Sep; 167(5):2126-33. PubMed ID: 22703941
[TBL] [Abstract][Full Text] [Related]
10. Late-term clinical outcomes with zotarolimus- and sirolimus-eluting stents. 5-year follow-up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions).
Kandzari DE; Mauri L; Popma JJ; Turco MA; Gurbel PA; Fitzgerald PJ; Leon MB
JACC Cardiovasc Interv; 2011 May; 4(5):543-50. PubMed ID: 21596327
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of rapamycin as compared to paclitaxel-eluting stents: a meta-analysis.
Juwana YB; Rasoul S; Ottervanger JP; Suryapranata H
J Invasive Cardiol; 2010 Jul; 22(7):312-6. PubMed ID: 20603502
[TBL] [Abstract][Full Text] [Related]
12. Five-year clinical outcomes in patients with diabetes mellitus treated with polymer-free sirolimus- and probucol-eluting stents versus second-generation zotarolimus-eluting stents: a subgroup analysis of a randomized controlled trial.
Harada Y; Colleran R; Kufner S; Giacoppo D; Rheude T; Michel J; Cassese S; Ibrahim T; Laugwitz KL; Kastrati A; Byrne RA;
Cardiovasc Diabetol; 2016 Sep; 15(1):124. PubMed ID: 27586678
[TBL] [Abstract][Full Text] [Related]
13. Randomized comparison of everolimus-eluting and sirolimus-eluting stents in patients treated with percutaneous coronary intervention: the Scandinavian Organization for Randomized Trials with Clinical Outcome IV (SORT OUT IV).
Jensen LO; Thayssen P; Hansen HS; Christiansen EH; Tilsted HH; Krusell LR; Villadsen AB; Junker A; Hansen KN; Kaltoft A; Maeng M; Pedersen KE; Kristensen SD; Bøtker HE; Ravkilde J; Sanchez R; Aarøe J; Madsen M; Sørensen HT; Thuesen L; Lassen JF;
Circulation; 2012 Mar; 125(10):1246-55. PubMed ID: 22308301
[TBL] [Abstract][Full Text] [Related]
14. Lack of clinical benefit of improved angiographic results with sirolimus-eluting stents compared with paclitaxel and zotarolimus-eluting stents in patients with acute myocardial infarction undergoing percutaneous coronary intervention.
Choi CU; Rha SW; Chen KY; Li YJ; Poddar KL; Jin Z; Minami Y; Suh SY; Na JO; Lim HE; Kim JW; Kim EJ; Park CG; Seo HS; Oh DJ
Circ J; 2009 Dec; 73(12):2229-35. PubMed ID: 19789418
[TBL] [Abstract][Full Text] [Related]
15. Outcomes with various drug-eluting or bare metal stents in patients with ST-segment-elevation myocardial infarction: a mixed treatment comparison analysis of trial level data from 34 068 patient-years of follow-up from randomized trials.
Bangalore S; Amoroso N; Fusaro M; Kumar S; Feit F
Circ Cardiovasc Interv; 2013 Aug; 6(4):378-90. PubMed ID: 23922145
[TBL] [Abstract][Full Text] [Related]
16. Randomized comparison of everolimus-eluting stent versus sirolimus-eluting stent implantation for de novo coronary artery disease in patients with diabetes mellitus (ESSENCE-DIABETES): results from the ESSENCE-DIABETES trial.
Kim WJ; Lee SW; Park SW; Kim YH; Yun SC; Lee JY; Park DW; Kang SJ; Lee CW; Lee JH; Choi SW; Seong IW; Lee BK; Lee NH; Cho YH; Shin WY; Lee SJ; Lee SW; Hyon MS; Bang DW; Park WJ; Kim HS; Chae JK; Lee K; Park HK; Park CB; Lee SG; Kim MK; Park KH; Choi YJ; Cheong SS; Yang TH; Jang JS; Her SH; Park SJ;
Circulation; 2011 Aug; 124(8):886-92. PubMed ID: 21810659
[TBL] [Abstract][Full Text] [Related]
17. Improved late clinical safety with zotarolimus-eluting stents compared with paclitaxel-eluting stents in patients with de novo coronary lesions: 3-year follow-up from the ENDEAVOR IV (Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease) trial.
Leon MB; Nikolsky E; Cutlip DE; Mauri L; Liberman H; Wilson H; Patterson J; Moses J; Kandzari DE;
JACC Cardiovasc Interv; 2010 Oct; 3(10):1043-50. PubMed ID: 20965463
[TBL] [Abstract][Full Text] [Related]
18. Long-term Outcomes of Paclitaxel-Eluting Versus Sirolimus-Eluting Stent for Percutaneous Coronary Intervention: AMeta-Analysis.
Kong J; Liu P; Fan X; Wen J; Zhang J; Zhen Y; Li J; Cui Y; Zheng X; Ye Z
J Coll Physicians Surg Pak; 2017 Jul; 27(7):432-439. PubMed ID: 28818167
[TBL] [Abstract][Full Text] [Related]
19. Very thin strut biodegradable polymer everolimus-eluting and sirolimus-eluting stents versus durable polymer zotarolimus-eluting stents in allcomers with coronary artery disease (BIO-RESORT): a three-arm, randomised, non-inferiority trial.
von Birgelen C; Kok MM; van der Heijden LC; Danse PW; Schotborgh CE; Scholte M; Gin RMTJ; Somi S; van Houwelingen KG; Stoel MG; de Man FHAF; Louwerenburg JHW; Hartmann M; Zocca P; Linssen GCM; van der Palen J; Doggen CJM; Löwik MM
Lancet; 2016 Nov; 388(10060):2607-2617. PubMed ID: 27806902
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Durable-Polymer Zotarolimus-Eluting and Biodegradable-Polymer Biolimus-Eluting Coronary Stents in Patients With Coronary Artery Disease: 3-Year Clinical Outcomes in the Randomized SORT OUT VI Trial.
Raungaard B; Christiansen EH; Bøtker HE; Hansen HS; Ravkilde J; Thuesen L; Aarøe J; Villadsen AB; Terkelsen CJ; Krusell LR; Maeng M; Kristensen SD; Veien KT; Hansen KN; Junker A; Madsen M; Andersen SL; Jensen SE; Jensen LO;
JACC Cardiovasc Interv; 2017 Feb; 10(3):255-264. PubMed ID: 28109874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
